Clinical Trial Update: Study to Evaluate the Efficacy and Safety of the Combination of Niraparib and Dostarlimab (TSR-042) in Participants With Platinum Resistant Ovarian Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial assessing niraparib combined with dostarlimab (TSR-042) in platinum-resistant ovarian cancer; study terminated with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ovarian Neoplasms

Drugs mentioned

• Dostarlimab (TSR-042) (dostarlimab)
• Niraparib (Niraparib)

Snippet

Sponsor: Tesaro, Inc. | Conditions: Ovarian Neoplasms | Phase 2 | Status: TERMINATED | Results posted: 2022-09-10